Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Mar 8;34(3):380-381.
doi: 10.1080/08998280.2021.1877509.

Erythema multiforme after treatment with sorafenib

Aaminah Faheem Azhar  1 , Rachael Camille Saporito  2 , Jordan Jamerson  2
Affiliations
Case Reports

Erythema multiforme after treatment with sorafenib

Aaminah Faheem Azhar et al. Proc (Bayl Univ Med Cent). .

Abstract

Sorafenib, an oral chemotherapeutic agent used in the treatment of solid tumors, is associated with a variety of adverse cutaneous drug reactions in up to 90% of patients. Infrequently, delayed-type hypersensitivity reactions such as erythema multiforme occur. This case describes a child treated with sorafenib for a retrosternal desmoid tumor who developed widespread erythema multiforme across his extremities, trunk, face, and mucosal membranes.

Keywords: Drug reaction; pharmacology; sorafenib.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Widespread erythematous edematous papules and plaques across face, trunk, extremities, and back.
See this image and copyright information in PMC

References

    1. Escudier B, Worden F, Kudo M.. Sorafenib: key lessons from over 10 years of experience. Expert Rev Anticancer Ther. 2019;19(2):177–189. doi:10.1080/14737140.2019.1559058. - DOI - PubMed
    1. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B.. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol. 2009;60(2):299–305. doi:10.1016/j.jaad.2008.06.034. - DOI - PubMed
    1. MacGregor JL, Silvers DN, Grossman ME, Sherman WH.. Sorafenib-induced erythema multiforme. J Am Acad Dermatol. 2007;56(3):527–528. doi:10.1016/j.jaad.2006.10.981. - DOI - PubMed
    1. Smith W. Adverse drug reactions—allergy? side-effect? intolerance? Aust Fam Physician. 2013;42(1-2):12–16. - PubMed
    1. Sokumbi O, Wetter DA.. Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. Int J Dermatol. 2012;51(8):889–902. doi:10.1111/j.1365-4632.2011.05348.x. - DOI - PubMed

Publication types

LinkOut - more resources